X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE AUROBINDO PHARMA SUVEN LIFE/
AUROBINDO PHARMA
 
P/E (TTM) x 21.1 19.3 109.3% View Chart
P/BV x 4.6 4.8 94.9% View Chart
Dividend Yield % 0.5 0.3 154.1%  

Financials

 SUVEN LIFE   AUROBINDO PHARMA
EQUITY SHARE DATA
    SUVEN LIFE
Mar-18
AUROBINDO PHARMA
Mar-17
SUVEN LIFE/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs251895 28.0%   
Low Rs155622 24.9%   
Sales per share (Unadj.) Rs49.1254.6 19.3%  
Earnings per share (Unadj.) Rs9.739.3 24.7%  
Cash flow per share (Unadj.) Rs11.446.6 24.5%  
Dividends per share (Unadj.) Rs1.502.50 60.0%  
Dividend yield (eoy) %0.70.3 224.3%  
Book value per share (Unadj.) Rs60.3160.0 37.7%  
Shares outstanding (eoy) m127.28585.88 21.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.13.0 138.6%   
Avg P/E ratio x20.919.3 108.1%  
P/CF ratio (eoy) x17.816.3 109.4%  
Price / Book Value ratio x3.44.7 71.0%  
Dividend payout %15.46.4 242.5%   
Avg Mkt Cap Rs m25,825444,390 5.8%   
No. of employees `0001.114.0 7.7%   
Total wages/salary Rs m61317,678 3.5%   
Avg. sales/employee Rs Th5,832.610,667.8 54.7%   
Avg. wages/employee Rs Th571.51,264.3 45.2%   
Avg. net profit/employee Rs Th1,153.81,645.8 70.1%   
INCOME DATA
Net Sales Rs m6,253149,157 4.2%  
Other income Rs m2331,159 20.1%   
Total revenues Rs m6,485150,316 4.3%   
Gross profit Rs m1,98234,343 5.8%  
Depreciation Rs m2134,276 5.0%   
Interest Rs m46667 6.9%   
Profit before tax Rs m1,95530,558 6.4%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7187,597 9.5%   
Profit after tax Rs m1,23723,012 5.4%  
Gross profit margin %31.723.0 137.7%  
Effective tax rate %36.724.9 147.8%   
Net profit margin %19.815.4 128.2%  
BALANCE SHEET DATA
Current assets Rs m5,62292,062 6.1%   
Current liabilities Rs m1,16866,223 1.8%   
Net working cap to sales %71.217.3 411.3%  
Current ratio x4.81.4 346.4%  
Inventory Days Days81106 76.8%  
Debtors Days Days3668 53.1%  
Net fixed assets Rs m3,32562,919 5.3%   
Share capital Rs m127586 21.7%   
"Free" reserves Rs m7,54793,133 8.1%   
Net worth Rs m7,67493,719 8.2%   
Long term debt Rs m141,814 0.8%   
Total assets Rs m9,135162,494 5.6%  
Interest coverage x43.246.8 92.4%   
Debt to equity ratio x00 9.4%  
Sales to assets ratio x0.70.9 74.6%   
Return on assets %14.014.6 96.4%  
Return on equity %16.124.6 65.6%  
Return on capital %26.032.7 79.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,06675,838 6.7%   
Fx outflow Rs m2,00130,224 6.6%   
Net fx Rs m3,06545,613 6.7%   
CASH FLOW
From Operations Rs m69932,786 2.1%  
From Investments Rs m-6-17,870 0.0%  
From Financial Activity Rs m-577-19,153 3.0%  
Net Cashflow Rs m116-4,239 -2.7%  

Share Holding

Indian Promoters % 63.4 54.1 117.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 8.0 -  
FIIs % 0.0 27.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 10.2 357.8%  
Shareholders   37,287 69,601 53.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare SUVEN LIFE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Sep 18, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE - FDC LTD. COMPARISON

COMPARE SUVEN LIFE WITH

MARKET STATS